Breathe Well Live Well
Conditions: Prednisone Dependent Asthma; Eosinophilic Bronchitis
Interventions: Biological: Omalizumab (Xolair); Drug: Placebo
Sponsors: McMaster University; Parameswaran Nair; Novartis
Not yet recruiting – verified January 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Xolair May Work for Nonallergic Asthma, Too
MedPage Today In severe, refractory nonatopic asthma, the drug effectively turned down immunoglobulin E receptor levels in inflammatory immune cells, Marc Humbert, MD, PhD, of Hôpital de Bicêtre, France, and colleagues found. The drug also reduced the degree of … |
View full post on asthma – Google News
|
Xolair May Work for Non-Allergic Asthma, Too
MedPage Today In severe, refractory nonatopic asthma, the drug effectively turned down immunoglobulin E receptor levels in inflammatory immune cells, Marc Humbert, MD, PhD, of Hôpital de Bicêtre, France, and colleagues found. The drug also reduced the degree of … |
View full post on asthma – Google News
French Tribune |
Novartis says asthma blockbuster Xolair also effective against serious hives
FiercePharma But Novartis says in financial filings that its pricing is under pressure for the asthma treatment. In the U.K., the price watchdog NICE last fall indicated it might drop approval of the drug there but then relented in March after Novartis offered up … Novartis reports new Phase III data showing omalizumab significantly improves … Novartis skin drug helps patients with chronic hives Novartis' omalizumab effective for severe hives |
View full post on asthma – Google News
|
Xolair gets asthma green light from NICE
PMLiVE The UK's National Institute for Health and Care Excellence (NICE) has recommended the use of Novartis' asthma injection Xolair as an add-on therapy on the NHS in England and Wales. The final guidance means Xolair (omalizumab) is now an option for … |
View full post on asthma – Google News
|
NICE Turnaround On Novartis' Xolair To Be Discussed At Asthma & Copd …
Big News Network.com asthma in adults, adolescents and children. The decision comes as a result of a move by Novartis to offer a patient access scheme to discount Xolair's list price. An estimated 65 million people currently suffer from COPD globally with 300 million … |
View full post on asthma – Google News
|
NICE U-turn on Novartis' Xolair for asthma
PharmaTimes The National Institute for Health and Clinical Excellence said it now recommends Xolair (omalizumab) as an option for treating severe, persistent allergic asthma in adults, adolescents and children, in a complete turnaround from its earlier intention … Asthma treatment – double U-turn Life-changing jab gives hope to asthma sufferers NICE approves use of asthma drug omalizumab |
View full post on asthma – Google News
 Daily Mail |
Xolair treatment for asthma sufferers: Don't scrap asthma jab that saved my …
Daily Mail Jack is one of 250,000 people in the UK with severe allergic asthma — a condition that occurs when the body detects a foreign body, such as house dust mites or pollen, but overreacts, producing large amounts of antibodies, triggering an allergic … |
View full post on asthma – Google News
|
New Irish study on Xolair and asthma
Irish Medical Times A recently published clinical paper shows that Xolair significantly reduces asthma exacerbations, hospitalisations and hospital bed days for Irish patients 1 . Patients with asthma who have persistent symptoms despite treatment with inhaled steroids … |
View full post on asthma – Google News
 AccentedTouch |
Norvatis' Xolair Aids In The Treatment of Asthma Among Children
AccentedTouch “A new study suggests that Novartis drug Xolair may aid in the treatment of asthma, the leading cause of chronic illness in children, especially for those living in highly polluted inner-city areas. Asthma affects as many as 10% to 12% of children in … |
View full post on asthma – Google News